It has been reported the use of nonsteroid anti-in‰ammatory drugs (NSAIDs) in late pregnancy was associated with potentially fetal toxicity (contraction of fetal ductus areteriosus). According to the package inserts in Japan, many oral NSAIDs are contraindicated to women in late pregnancy, but several oral and topical NSAIDs with case reports of fetal toxicity are not. In the present study, a web-based questionnaire survey was conducted in pharmacists/physicians to determine their awareness of fetal toxicity caused by NSAIDs, as well as their attitudes regarding the use of NSAIDs in late pregnancy. Responses were obtained from 427 pharmacists, 22 obstetricians, and 160 non-obstetric physicians. Of the non-obstetric respondents, more than 40％ had no knowledge of fetal ductus arteriosus contraction caused by oral ibuprofen, and most of them were not aware of the relevant warning statement on the package insert. In contrast, these were familiar to nearly 100％ of the obstetricians. As for ketoprofen tape, only 20 40％ of the pharmacists/physicians were aware of the warning statement, and nearly all respondents did not conˆrm whether the patient was in late pregnancy. The majority of the respondents answered that oral ibuprofen, ketoprofen tape and NSAID-containing OTC drugs should not be used in late pregnancy after they knew the warning statements in late pregnancy. This survey suggests that the fetal toxicity of NSAIDs is not well recognized by pharmacists/physicians. It would be necessary to make it thoroughly known to them through such as enrichment of safety information on the package inserts, accompanying with the evidence.
No statement 29) For the OTC drugs, the package inserts of products containing any ingredient of the interest were comprehensively reviewed, and the warning statement used for the majority is shown. The representative references are shown by reference numbers. Responses to question,``What do you think about the use of oral ibuprofen, ketoprofen tape, or other topical NSAIDs in late pregnancy?'' are shown. n (％). a For oral ibuprofen, the same question was asked twice, before (``without information about naproxen'') and after (``with information about naproxen'') information about the revision of the package insert of naproxen, which is similar to ibuprofen in that no serious adverse fetal eŠects have been reported and is now contraindicated in late pregnancy according to the latest package insert, was received. Responses to questions,``Do you conˆrm whether the female patient is in late pregnancy before ketoprofen tape is prescribed/administered?'' and``Do you know that ketoprofen tape should be administered with care in late pregnancy?'' are shown. n (％), pharmacists who haveˆlled a prescription for ketoprofen tape and physicians who have prescribed it: no responses were obtained from 2 pharmacists or 1 non-obstetric physician, to at least one question, a four-fold point correlation coe‹cient. Responses to questions,``Have you been consulted by any woman in late pregnancy about the use of NSAID-containing OTC drugs?'',``Do you know that some OTC drugs are described as contraindicated in pregnancy or late pregnancy?'', and``Do you know that some OTC drugs are not described as contraindicated in pregnancy or late pregnancy?'' are shown. n (％). 
